Wedbush Securities Inc Clovis Oncology, Inc. Transaction History

Wedbush Securities Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	BUY	$0.63 - $2.96 $315 - $1,480	500 Added 2.54%	20,200 $36,000
Q1 2022 Apr 19, 2022	SELL	$1.43 - $3.14 $214 - $471	-150 Reduced 0.76%	19,700 $39,000
Q4 2021 Jan 13, 2022	SELL	$2.7 - $4.76 $14,850 - $26,180	-5,500 Reduced 21.7%	19,850 $53,000
Q3 2021 Oct 08, 2021	BUY	$4.06 - $5.8 $7,307 - $10,440	1,800 Added 7.64%	25,350 $113,000
Q2 2021 Jul 27, 2021	BUY	$5.02 - $7.05 $19,578 - $27,495	3,900 Added 19.85%	23,550 $136,000
Q1 2021 Apr 26, 2021	BUY	$4.81 - $10.34 $9,139 - $19,646	1,900 Added 10.7%	19,650 $137,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $7,434 - $11,538	1,800 Added 11.29%	17,750 $85,000
Q3 2020 Oct 20, 2020	BUY	$4.82 - $7.72 $14,460 - $23,160	3,000 Added 23.17%	15,950 $93,000
Q2 2020 Jul 16, 2020	BUY	$5.69 - $9.69 $73,685 - $125,485	12,950 New	12,950 $87,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.